SCHEMBL21223535

SCHEMBL21223535

COc1nc(N)ccc1-c1cccc(Cl)c1Cl

nearest known ligand 0.47

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
NUDT1 P36639 6/20 0.47
CD274 Q9NZQ7 11/20 0.43
PDCD1LG2 Q9BQ51 8/20 0.43
CYP2D6 P10635 1/20 0.42
MAOA P21397 1/20 0.42
MAPK1 P28482 1/20 0.42
ADRA1A P35348 1/20 0.42
SCN4A P35499 1/20 0.42
BLM P54132 1/20 0.42
PMP22 Q01453 1/20 0.42
PDE3A Q14432 1/20 0.42
SCN5A Q14524 1/20 0.42
SCN9A Q15858 1/20 0.42
SCN2A Q99250 1/20 0.42
SCN3A Q9NY46 1/20 0.42
SCN10A Q9Y5Y9 1/20 0.42
PDCD1 Q15116 3/20 0.42
PTPN11 Q06124 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL21223742 0.80 PTPN11 (0.40) NUDT1CD274PDCD1LG2CYP2D6MAOA
SCHEMBL4504455 0.79 NUDT1 (0.47) NUDT1CYP2D6MAOAMAPK1ADRA1A
Hydrochloric Acid SCHEMBL21223601 0.79 PTPN11 (0.39) NUDT1CD274PDCD1LG2CYP2D6MAOA
SCHEMBL264853 0.78 SCN9A (0.51) NUDT1CYP2D6MAOAMAPK1ADRA1A
SCHEMBL21223512 0.76 NUDT1 (0.44) NUDT1CYP2D6MAOAMAPK1ADRA1A
SCHEMBL21244573 0.76 APP (0.50)
SCHEMBL21223455 0.76 NUDT1 (0.46) NUDT1CD274PDCD1LG2CYP2D6MAOA
SCHEMBL21222978 0.75 PTPN1 (0.51) NUDT1CD274CYP2D6MAOAMAPK1
SCHEMBL18322990 0.75 CD274 (0.45) NUDT1CD274PDCD1LG2PDCD1PTPN11
SCHEMBL6690974 0.74 CRHBP (0.41) CD274PDCD1LG2MAPK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20210221784-A1 COMPOUNDS AND COMPOSITIONS FOR THE TREATMENT OF PAIN UNIVERSITÉ DE STRASBOURG (FR) 2021-07-22 US claimed
EP-3749305-A1 COMPOUNDS AND COMPOSITIONS FOR THE TREATMENT OF PAIN Université de Strasbourg (FR) 2020-12-16 EP claimed
CN-111683660-A Compounds and compositions for the treatment of pain 斯特拉斯堡大学 2020-09-18 CN claimed
WO-2019149965-A1 COMPOUNDS AND COMPOSITIONS FOR THE TREATMENT OF PAIN UNIVERSITE DE STRASBOURG (FR) 2019-08-08 WO claimed
US-20210221784-A1 COMPOUNDS AND COMPOSITIONS FOR THE TREATMENT OF PAIN UNIVERSITÉ DE STRASBOURG (FR) 2021-07-22 US disclosed
EP-3749305-A1 COMPOUNDS AND COMPOSITIONS FOR THE TREATMENT OF PAIN Université de Strasbourg (FR) 2020-12-16 EP disclosed
CN-111683660-A Compounds and compositions for the treatment of pain 斯特拉斯堡大学 2020-09-18 CN disclosed
WO-2019149965-A1 COMPOUNDS AND COMPOSITIONS FOR THE TREATMENT OF PAIN UNIVERSITE DE STRASBOURG (FR) 2019-08-08 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20210221784-A1 COMPOUNDS AND COMPOSITIONS FOR THE TREATMENT OF PAIN ACHE, TRPV1, OPRL1 NUDT1 972/4885CD274 4661/4885PDCD1LG2 4842/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.